![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() by Staff Writers Brisbane, Australia (SPX) Jan 08, 2018
An old drug supercharged by University of Queensland researchers has emerged as a new antibiotic that could destroy some of the world's most dangerous superbugs. The supercharge technique , led by Dr Mark Blaskovich and Professor Matt Cooper from UQ's Institute for Molecular Bioscience (IMB), potentially could revitalise other antibiotics. Antibiotic-resistant bacteria - superbugs - cause 700,000 deaths worldwide each year, and a UK government review has predicted this could rise to 10 million by 2050. Dr Blaskovich said the old drug, vancomycin, was still widely used to treat extremely dangerous bacterial infections, but bacteria were becoming increasingly resistant to it. "The rise of vancomycin-resistant bacteria, and the number of patients dying from resistant infections that cannot be successfully treated, stimulated our team to look at ways to revitalise old antibiotics," Dr Blaskovich said. "We did this by modifying vancomycin's membrane-binding properties to selectively bind to bacterial membranes rather than those of human cells, creating a series of supercharged vancomycin derivatives called vancapticins." The rebooted vancomycin has the potential to treat methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). Professor Cooper said pharmaceutical companies had departed the antibiotic discovery field because new antibiotics were difficult to find and were not as lucrative as cholesterol-lowering medications or cancer treatments. "Hence many scientists are re-engineering existing drugs to overcome bacterial resistance, rather than searching for new drugs," he said. "Drug development is normally focused on improving binding to a biological target, and rarely focuses on assessing membrane-binding properties. "This approach worked with the vancapticins, and the question now is whether it can be used to revitalise other antibiotics that have lost effectiveness against resistant bacteria. "Given the alarming rise of multi-drug resistant bacteria and the length of time it takes to develop a new antibiotic, we need to look at any solution that could fix the antibiotic drug discovery pipeline now," Professor Cooper said.
![]() Washington DC (SPX) Jan 02, 2018 Uganda is among the countries is sub-Saharan Africa where cholera remains a recurring problem, despite advances in science and technology for prevention, detection and treatment of the infectious disease. Now, researchers reporting in PLOS Neglected Tropical Diseases have identified cholera hotspots around Uganda to help target interventions. Cholera, caused by ingestion of food or water c ... read more Related Links University of Queensland Epidemics on Earth - Bird Flu, HIV/AIDS, Ebola
![]()
![]() |
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |